A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.

El-Khoueiry AB, Lieu CH, Abou-Alfa GK, Tsimberidou AM, Mahadevan D, Hanna DL, Bockorny B, Wilky BA, Leal A, Stebbing J, Avagyan M, Wu W, Chand D, Grossman JE, Johnson B, Bullock AJ

Open source

DOI: 10.1159/000551630
Published: 2026 Mar 30
Container: Liver cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000551630,
  title = {A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.},
  author = {El-Khoueiry AB and Lieu CH and Abou-Alfa GK and Tsimberidou AM and Mahadevan D and Hanna DL and Bockorny B and Wilky BA and Leal A and Stebbing J and Avagyan M and Wu W and Chand D and Grossman JE and Johnson B and Bullock AJ},
  year = {2026},
  journal = {Liver cancer},
  doi = {10.1159/000551630},
  url = {https://doi.org/10.1159/000551630}
}

RIS

TY  - JOUR
TI  - A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
AU  - El-Khoueiry AB
AU  - Lieu CH
AU  - Abou-Alfa GK
AU  - Tsimberidou AM
AU  - Mahadevan D
AU  - Hanna DL
AU  - Bockorny B
AU  - Wilky BA
AU  - Leal A
AU  - Stebbing J
AU  - Avagyan M
AU  - Wu W
AU  - Chand D
AU  - Grossman JE
AU  - Johnson B
AU  - Bullock AJ
PY  - 2026
JO  - Liver cancer
DO  - 10.1159/000551630
UR  - https://doi.org/10.1159/000551630
ER  -

APA

AB, E., CH, L., GK, A., AM, T., D, M., DL, H., B, B., BA, W., A, L., J, S., M, A., W, W., D, C., JE, G., B, J., & AJ, B. (2026). A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.. Liver cancer. https://doi.org/10.1159/000551630

Source records

pubmed · retrieved 2026-09-25T01:46:31.799Z